|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
Low-molecular weight NGF mimetic attenuates the manifestation of diabetic neuropathy (experimental study)статья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или ScopusДата последнего поиска статьи во внешних источниках: 8 сентября 2021 г.
- Авторы: Ivanov S., Khlybova A., Yagubova S., Ostrovskaya R., Gudasheva T.
- Журнал: European Neuropsychopharmacology
- Том: 44
- Номер: 12
- Год издания: 2021
- Издательство: Elsevier BV
- Местоположение издательства: Netherlands
- Первая страница: 27
- Последняя страница: 28
- DOI: 10.1016/j.euroneuro.2021.01.047
- Аннотация: Diabetic neuropathy is one of the most common complications of diabetes mellitus (DM), occurring in 30-65% of patients. There are a lot of literature data concerning the important role of neurotrophins deficit in the pathogenesis of DM. However, the unsatisfactory pharmacokinetic properties of full-size neurotrophin impede its usage for the replacement therapy. Based on NGF 4th loop β-turn, a low-molecular weight NGF mimetic “GK-2” (hexamethylenediamine bis-(N-monosuccinyl-L-glutamyl-L-lysine)) was created in V.V. Zakusov Research Institute of Pharmacology. This compound as well as other low-molecular weight NGF and BDNF mimetics exert the activity under systemic administration and has no side effects of full-size neurotrophins. GK-2 demonstrated a pronounced neuroprotective activity in vitro and in vivo. The aim of this study is to evaluate effect of GK-2 on the model of diabetic neuropathy.
- Добавил в систему: Иванов Сергей Витальевич